Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The endocrine effects of aminoglutethimide 125 mg twice daily and hydrocortisone 20 mg twice daily were assessed in 45 postmenopausal women with advanced breast cancer. Oestrone and oestradiol levels were suppressed by 60% within 2 weeks and suppression was maintained for more than 6 months of chronic treatment. In contrast to conventional dose AG with hydrocortisone, or low dose AG without hydrocortisone, delta 4 androstenedione was suppressed by 65%. This effect may contribute to optimal oestrogen suppression.

Type

Journal article

Journal

Breast Cancer Res Treat

Publication Date

1986

Volume

7 Suppl

Pages

S69 - S72

Keywords

Aminoglutethimide, Androstenedione, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dehydroepiandrosterone, Estradiol, Estrone, Female, Humans, Hydrocortisone, Menopause